Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System

Paul D. Harker-Murray, Avis J. Thomas, John E. Wagner, Daniel Weisdorf, Xianghua Luo, Todd E. DeFor, Michael R. Verneris, Kathryn E. Dusenbery, Margaret L. MacMillan, Jakub Tolar, K. Scott Baker, Paul J. Orchard

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is the standard of care for pediatric patients with early medullary relapse of acute lymphoblastic leukemia (ALL). Most patients with isolated central nervous system (CNS) relapse have good outcomes when treated with intrathecal and systemic chemotherapy followed by irradiation to the neuroaxis. However, the role of HCT remains unclear for those patients with early isolated CNS relapse (<18 months) or who had high risk disease at diagnosis. We therefore compared the HCT outcomes of 116 children treated at the University of Minnesota from 1991 to 2006 with relapsed ALL involving the CNS alone (CNS, n = 14), the bone marrow alone (BM, n = 85), or both bone marrow and CNS (BM + CNS, n = 17). There were no significant differences among groups in age at diagnosis or transplant, length of first complete remission (CR1), remission status (CR2 versus ≥CR3), graft source, or preparative regimen. The incidence of acute GVHD was similar between groups. Patients with isolated CNS relapse had the lowest cumulative incidence of mortality following transplant (CNS: 0%, BM: 19%, BM + CNS: 29%, P = .03) and relapse (CNS: 0% BM: 30%, BM + CNS: 12%, at 2 years, P = .01) and highest leukemia-free survival (CNS: 91%, BM: 35%, BM + CNS: 46%, P < .01) at 5 years. Risk factors for poor survival were: T cell leukemia or BCR-ABL gene rearrangement, history of marrow relapse, and receipt of HLA-mismatched marrow. These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse.

Original languageEnglish (US)
Pages (from-to)685-692
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System
Recurrence
Bone Marrow
Transplants
T-Cell Leukemia
Survival
Gene Rearrangement
Incidence
Standard of Care
Leukemia

Keywords

  • Acute lymphocytic leukemia
  • Bone marrow
  • CNS relapse
  • Graft-versus-host disease
  • Stem cell
  • Umbilical cord blood

ASJC Scopus subject areas

  • Transplantation

Cite this

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. / Harker-Murray, Paul D.; Thomas, Avis J.; Wagner, John E.; Weisdorf, Daniel; Luo, Xianghua; DeFor, Todd E.; Verneris, Michael R.; Dusenbery, Kathryn E.; MacMillan, Margaret L.; Tolar, Jakub; Baker, K. Scott; Orchard, Paul J.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 6, 06.2008, p. 685-692.

Research output: Contribution to journalArticle

Harker-Murray, PD, Thomas, AJ, Wagner, JE, Weisdorf, D, Luo, X, DeFor, TE, Verneris, MR, Dusenbery, KE, MacMillan, ML, Tolar, J, Baker, KS & Orchard, PJ 2008, 'Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System', Biology of Blood and Marrow Transplantation, vol. 14, no. 6, pp. 685-692. https://doi.org/10.1016/j.bbmt.2008.03.011
Harker-Murray, Paul D. ; Thomas, Avis J. ; Wagner, John E. ; Weisdorf, Daniel ; Luo, Xianghua ; DeFor, Todd E. ; Verneris, Michael R. ; Dusenbery, Kathryn E. ; MacMillan, Margaret L. ; Tolar, Jakub ; Baker, K. Scott ; Orchard, Paul J. / Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 6. pp. 685-692.
@article{6b3dcff482af49f085f35a9794f6bb5b,
title = "Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) is the standard of care for pediatric patients with early medullary relapse of acute lymphoblastic leukemia (ALL). Most patients with isolated central nervous system (CNS) relapse have good outcomes when treated with intrathecal and systemic chemotherapy followed by irradiation to the neuroaxis. However, the role of HCT remains unclear for those patients with early isolated CNS relapse (<18 months) or who had high risk disease at diagnosis. We therefore compared the HCT outcomes of 116 children treated at the University of Minnesota from 1991 to 2006 with relapsed ALL involving the CNS alone (CNS, n = 14), the bone marrow alone (BM, n = 85), or both bone marrow and CNS (BM + CNS, n = 17). There were no significant differences among groups in age at diagnosis or transplant, length of first complete remission (CR1), remission status (CR2 versus ≥CR3), graft source, or preparative regimen. The incidence of acute GVHD was similar between groups. Patients with isolated CNS relapse had the lowest cumulative incidence of mortality following transplant (CNS: 0{\%}, BM: 19{\%}, BM + CNS: 29{\%}, P = .03) and relapse (CNS: 0{\%} BM: 30{\%}, BM + CNS: 12{\%}, at 2 years, P = .01) and highest leukemia-free survival (CNS: 91{\%}, BM: 35{\%}, BM + CNS: 46{\%}, P < .01) at 5 years. Risk factors for poor survival were: T cell leukemia or BCR-ABL gene rearrangement, history of marrow relapse, and receipt of HLA-mismatched marrow. These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse.",
keywords = "Acute lymphocytic leukemia, Bone marrow, CNS relapse, Graft-versus-host disease, Stem cell, Umbilical cord blood",
author = "Harker-Murray, {Paul D.} and Thomas, {Avis J.} and Wagner, {John E.} and Daniel Weisdorf and Xianghua Luo and DeFor, {Todd E.} and Verneris, {Michael R.} and Dusenbery, {Kathryn E.} and MacMillan, {Margaret L.} and Jakub Tolar and Baker, {K. Scott} and Orchard, {Paul J.}",
year = "2008",
month = "6",
doi = "10.1016/j.bbmt.2008.03.011",
language = "English (US)",
volume = "14",
pages = "685--692",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System

AU - Harker-Murray, Paul D.

AU - Thomas, Avis J.

AU - Wagner, John E.

AU - Weisdorf, Daniel

AU - Luo, Xianghua

AU - DeFor, Todd E.

AU - Verneris, Michael R.

AU - Dusenbery, Kathryn E.

AU - MacMillan, Margaret L.

AU - Tolar, Jakub

AU - Baker, K. Scott

AU - Orchard, Paul J.

PY - 2008/6

Y1 - 2008/6

N2 - Allogeneic hematopoietic cell transplantation (HCT) is the standard of care for pediatric patients with early medullary relapse of acute lymphoblastic leukemia (ALL). Most patients with isolated central nervous system (CNS) relapse have good outcomes when treated with intrathecal and systemic chemotherapy followed by irradiation to the neuroaxis. However, the role of HCT remains unclear for those patients with early isolated CNS relapse (<18 months) or who had high risk disease at diagnosis. We therefore compared the HCT outcomes of 116 children treated at the University of Minnesota from 1991 to 2006 with relapsed ALL involving the CNS alone (CNS, n = 14), the bone marrow alone (BM, n = 85), or both bone marrow and CNS (BM + CNS, n = 17). There were no significant differences among groups in age at diagnosis or transplant, length of first complete remission (CR1), remission status (CR2 versus ≥CR3), graft source, or preparative regimen. The incidence of acute GVHD was similar between groups. Patients with isolated CNS relapse had the lowest cumulative incidence of mortality following transplant (CNS: 0%, BM: 19%, BM + CNS: 29%, P = .03) and relapse (CNS: 0% BM: 30%, BM + CNS: 12%, at 2 years, P = .01) and highest leukemia-free survival (CNS: 91%, BM: 35%, BM + CNS: 46%, P < .01) at 5 years. Risk factors for poor survival were: T cell leukemia or BCR-ABL gene rearrangement, history of marrow relapse, and receipt of HLA-mismatched marrow. These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse.

AB - Allogeneic hematopoietic cell transplantation (HCT) is the standard of care for pediatric patients with early medullary relapse of acute lymphoblastic leukemia (ALL). Most patients with isolated central nervous system (CNS) relapse have good outcomes when treated with intrathecal and systemic chemotherapy followed by irradiation to the neuroaxis. However, the role of HCT remains unclear for those patients with early isolated CNS relapse (<18 months) or who had high risk disease at diagnosis. We therefore compared the HCT outcomes of 116 children treated at the University of Minnesota from 1991 to 2006 with relapsed ALL involving the CNS alone (CNS, n = 14), the bone marrow alone (BM, n = 85), or both bone marrow and CNS (BM + CNS, n = 17). There were no significant differences among groups in age at diagnosis or transplant, length of first complete remission (CR1), remission status (CR2 versus ≥CR3), graft source, or preparative regimen. The incidence of acute GVHD was similar between groups. Patients with isolated CNS relapse had the lowest cumulative incidence of mortality following transplant (CNS: 0%, BM: 19%, BM + CNS: 29%, P = .03) and relapse (CNS: 0% BM: 30%, BM + CNS: 12%, at 2 years, P = .01) and highest leukemia-free survival (CNS: 91%, BM: 35%, BM + CNS: 46%, P < .01) at 5 years. Risk factors for poor survival were: T cell leukemia or BCR-ABL gene rearrangement, history of marrow relapse, and receipt of HLA-mismatched marrow. These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse.

KW - Acute lymphocytic leukemia

KW - Bone marrow

KW - CNS relapse

KW - Graft-versus-host disease

KW - Stem cell

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=43449139122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449139122&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.03.011

DO - 10.1016/j.bbmt.2008.03.011

M3 - Article

VL - 14

SP - 685

EP - 692

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -